Controlled trials have demonstrated that the treatment of HIV-infected women during pregnancy with antiretroviral agents, such as zidovudine (AZT), can dramatically lower the risk of maternal-neonatal HIV transmission. 4, 5 We have recently demonstrated that knowledge about such therapies is limited among inner-city women at high risk for HIV infection, though the availability of medicine to lower the risk of vertical HIV transmission, even in the absence of clear maternal benefit, was viewed almost uniformly by these women as both important and acceptable. 6 
